首页> 外文OA文献 >Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

【2h】

Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

机译：TLR7激动剂脯氨酸的脂质缀合可确保与脂质体阳离子佐剂制剂01（CAF01）共递送，但与非共轭份替代+ CAF01相比，不增强免疫稳定性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Alexander Wilkinson; Eric Lattmann; Carla B. Roces; Gabriel K. Pedersen; Dennis Christensen; Yvonne Perrie;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01 [J] . Wilkinson Alexander, Lattmann Eric, Roces Carla B., Journal of Controlled Release: Official Journal of the Controlled Release Society . 2018,第期

机译：TLR7激动剂脯氨酸的脂质缀合可确保与脂质体阳离子佐剂制剂01（CAF01）共递送，但与非共轭份替代+ CAF01相比，不增强免疫稳定性
2. Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles [J] . Thakur Aneesh, Rose Fabrice, Ansari Shaquib Rahman, Molecular pharmaceutics . 2019,第11期

机译：用于肺沉积肺部施用颗粒的肺沉积MRI的Gadoteridol负载阳离子脂质体佐剂CAF01的设计
3. High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation [J] . Adam J.R. Gadd, Valeria Castelletto, Elena Kabova, European journal of pharmaceutical sciences . 2018,第期

机译：脂质缀合的TLR7激动剂的高效力需要纳米颗粒或脂质体配方
4. High potency of lipid conjugated TLR7 agonist requires nanoparticulate or liposomal formulation [O] . Adam J.R. Gadd, Valeria Castelletto, Elena Kabova, -1

机译：脂质缀合的TLR7激动剂的高效力需要纳米颗粒或脂质体制剂

Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

著录项

相似文献

相关主题

期刊订阅